Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX)

CASRN 121-82-4

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (15 pp, 125 K) last updated: 09/26/1988

System RfD (mg/kg-day) Basis PoD Composite UF Confidence
Reproductive 3 x 10-3 Inflammation of the prostate NOEL : 3 x 10-1
100 High


Reference Concentration for Inhalation Exposure (RfC) (PDF) (15 pp, 125 K)
Not assessed under the IRIS Program.


Cancer Assessment

Weight of Evidence for Cancer (PDF) (15 pp, 125 K) last updated: 08/01/1990

WOE Characterization Framework for WOE Characterization
C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
  • Hepatocellular adenomas and carcinomas in female B6C3F1 mice.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (15 pp, 125 K)

Oral Slope Factor: 1.1 x10 -1 per mg/kg-day
Drinking Water Unit Risk: 3.1 x10 -6 per µg/L
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Hepatic
Tumor type(s): Liver, hepatocellular carcinoma, and adenomas (combined) (U.S. DOD, 1984)

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (15 pp, 125 K)

Not Assessed under the IRIS Program.

Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) is being reassessed.

Assessment Manager(s): Louis D'Amico (

Step Assessment Materials Released to the Public Release Date Public Meeting Date
1 Problem Formulation Materials N/A N/A
1 Preliminary Assessment Materials 08/2013 12/2013
4 Public Comment Draft 03/2016 05/2016
4 Peer Review Draft 09/2016 12/2016
7 Post Final Assessment TBD

Please note: Any future dates displayed under Release Date are estimates and subject to change.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.

Quick Check